Cetuximab News and Research

RSS

Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.

12 Sep 2023

The Clinical Importance of Circulating Tumor DNA

Cancer remains a leading killer among medical causes of death worldwide.

31 Aug 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Researchers investigated the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma.

31 Jul 2023

Cetuximab plus radiotherapy effective in treating locally advanced cutaneous squamous cell cancer

A new research paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, "Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series."

12 Jul 2023

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

Researchers from the Organoid group (Hubrecht Institute) and UMC Utrecht have developed a biobank with organoids derived from patients with head and neck cancer (HNC).

12 May 2023

New combination therapy shows promising results in some patients with advanced head and neck cancer

A new combination drug treatment showed promising results in patients with pan-refractory, recurrent/metastatic head and neck cancer, according to a study published today in the Journal of Clinical Oncology.

28 Mar 2023

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

MIT chemists discover how changes in a shape-shifting receptor trigger cell growth

Receptors found on cell surfaces bind to hormones, proteins, and other molecules, helping cells respond to their environment.

6 Jul 2022

Salk study could help find better treatment options for colorectal cancer patients

Patients with colorectal cancer were among the first to receive targeted therapies. These drugs aim to block the cancer-causing proteins that trigger out-of-control cell growth while sparing healthy tissues.

14 Dec 2021

Topical therapy can help safely reduce side effect of cancer treatment

Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.

28 Apr 2021

Salk joins a long list of recipients included in The Conrad Prebys Foundation’s inaugural grant cycle

Salk Professor Thomas Albright has been awarded $1 million and Assistant Professor Edward Stites awarded $500,000 by The Conrad Prebys Foundation as part of its inaugural round of grants.

26 Mar 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.

26 Aug 2020

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the 'progression free survival' time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

30 May 2020

Cetuximab News and Research

Further Reading

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

The Clinical Importance of Circulating Tumor DNA

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Cetuximab plus radiotherapy effective in treating locally advanced cutaneous squamous cell cancer

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

New combination therapy shows promising results in some patients with advanced head and neck cancer

CAR T-cell therapy in colorectal cancer

MIT chemists discover how changes in a shape-shifting receptor trigger cell growth

Salk study could help find better treatment options for colorectal cancer patients

Topical therapy can help safely reduce side effect of cancer treatment

Salk joins a long list of recipients included in The Conrad Prebys Foundation’s inaugural grant cycle

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Turning autoimmunity drugs into anti-cancer treatments

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

SU2C commends FDA’s approval of new cancer therapy

Study: Chemoradiation regimen for Stage III NSCLC is better than two tested alternatives

Understanding Monoclonal Antibody Unfolding and Aggregation

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News